Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Jacqui Nimmo(UK Dementia Research Institute), James A. R. Nicoll(University of Southampton), Ajay Verma, Ronald Melki(Institut des Neurosciences Paris-Saclay), Roxana O. Carare(University of Southampton), Jean‐Cosme Dodart, Chang Yi Wang(Asia University), Jimmy Savistchenko(Centre National de la Recherche Scientifique)
Cited by 2
Related Papers
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
UB‐311, a novel UBITh <sup>®</sup> amyloid β peptide vaccine for mild Alzheimer's disease
|Alzheimer s & Dementia Translational Research & Clinical Interventions|2017|142
Molecular Interaction between the Chaperone Hsc70 and the N-terminal Flank of Huntingtin Exon 1 Modulates Aggregation
|Journal of Biological Chemistry|2014|85
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
|Movement Disorders|2022|51
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
|Alzheimer s Research & Therapy|2020|48